InnovAge (INNV) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
22 Oct, 2026Executive summary
Annual meeting scheduled for December 3, 2026, at 9:00 a.m. EST, virtually; voting deadline is December 2, 2026, at 11:59 p.m. EST.
Voting matters and shareholder proposals
Stockholders will vote on four Class III director nominees, say-on-pay frequency, executive compensation approval, and auditor ratification; the board recommends For each nominee and proposal, and Year for say-on-pay frequency.
Board of directors and corporate governance
Class III director nominees are John Ellis Bush, Patricia Fontneau, Ted Kennedy, Jr., and Pavithra Mahesh; the board recommends For all four.
Partial view of Summaries dataset, powered by Quartr API
Latest events from InnovAge
- Annual votes cover four directors, executive pay, say-on-pay frequency, and auditor ratification.INNV
Proxy filing - 2027 guidance targets $105–$115 million adjusted EBITDA, reflecting strong growth and margin expansion.INNV
Wells Fargo 21st Annual Healthcare Conference - Strong revenue and margin growth in 2026 set the stage for disciplined, tech-driven expansion in 2027.INNV
Q4 2026 - Revenue up 15.1%, net income positive, strong census growth, FY2026 guidance reaffirmed.INNV
Q1 2026 - Revenue up 11.8%, adjusted EBITDA doubled, and margin expanded; FY26 outlook remains strong.INNV
Q4 2025 - Revenue up 12.4%, net loss halved, and Adjusted EBITDA margin improved to 3.2%.INNV
Q1 2025 - Revenue up 11% to $764M, margins improved, FY25 guidance strong despite regulatory headwinds.INNV
Q4 2024 - Revenue up 13%, adjusted EBITDA rose to $10.8M, but net loss widened on higher costs.INNV
Q3 2025 - Revenue up 10.6% to $209M; FY2025 guidance reaffirmed amid margin and regulatory pressures.INNV
Q2 2025